Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06939803 · ClinicalTrials.gov registry record · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
A NA study of Venothromboembolism, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 2,236
- Enrollment target
- 1
- Study location
NCT06939803: Recruiting NA study of Venothromboembolism, sponsored by Vanderbilt University Medical Center.
NCT06939803 is a NA study of Venothromboembolism that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 2,236 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06939803, a NA study of Venothromboembolism, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,236 participants
- Enrollment target
- 1
- Study location
Study Summary
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health issues and deaths in both adults and children. About 1 in 3 people who get blood clots experience long-term complications. Reducing HA-VTE is a major challenge. This study will test a new AI method to predict and prevent HA-VTE. The goal is to see if this AI tool can reduce the number of HA-VTE cases in the Vanderbilt Health System, which includes both urban and rural hospitals. The AI tool, called VTE-AI, calculates a risk score without needing input from doctors. It will suggest reconsidering blood clot prevention measures for patients who don't have them ordered and have no reasons to avoid them. This suggestion will be made after admission and daily during the hospital stay. Currently, doctors manually calculate a risk score and choose a prevention option. This study will compare the effectiveness of the AI tool against the current manual method in reducing HA-VTE cases. The study will randomly assign half of the patients to use the AI tool and the other half to the standard manual method.
Primary Outcome
Percentage of admissions in which patients were diagnosed with VTE more than 48 hours after admission, defined as "Hospital Acquired" in prior literature
Conditions Studied
Interventions
- OTHER Risk model-driven CDS
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,236 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT06939803 shows while recruiting
NCT06939803 is an interventional study that assigns participants to a tested intervention. Its 2,236 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Venothromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Risk model-driven CDS is the first listed.
NCT06939803 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06939803 about?
NCT06939803 is a clinical study titled "AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.". Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health ...
What is the current status of trial NCT06939803?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,236 participants. The study started on 2025-12-17. Estimated completion is 2027-03-31.
What conditions does trial NCT06939803 study?
This clinical trial studies the following conditions: Venothromboembolism.
What interventions are being tested in trial NCT06939803?
The interventions under investigation include: Risk model-driven CDS (OTHER).
Who is sponsoring clinical trial NCT06939803?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06939803 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06939803's enrollment target sits among peer trials
2,236 48th of 2000 higher than 1,953 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI